Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Market Place
ABOUT THIS PAGE
A Tranilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tranilast, including repackagers and relabelers. The FDA regulates Tranilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tranilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tranilast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tranilast supplier is an individual or a company that provides Tranilast active pharmaceutical ingredient (API) or Tranilast finished formulations upon request. The Tranilast suppliers may include Tranilast API manufacturers, exporters, distributors and traders.
click here to find a list of Tranilast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tranilast Drug Master File in Japan (Tranilast JDMF) empowers Tranilast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tranilast JDMF during the approval evaluation for pharmaceutical products. At the time of Tranilast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tranilast suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tranilast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tranilast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tranilast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tranilast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tranilast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tranilast suppliers with NDC on PharmaCompass.
Tranilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tranilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tranilast GMP manufacturer or Tranilast GMP API supplier for your needs.
A Tranilast CoA (Certificate of Analysis) is a formal document that attests to Tranilast's compliance with Tranilast specifications and serves as a tool for batch-level quality control.
Tranilast CoA mostly includes findings from lab analyses of a specific batch. For each Tranilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tranilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Tranilast EP), Tranilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tranilast USP).
LOOKING FOR A SUPPLIER?
